
HCA Healthcare Partners with GRAIL to Offer Galleri Liquid Biopsy Test
HCA Healthcare, the largest hospital system in the U.S. with 182 hospitals and over 2,300 care sites, and GRAIL have announced a strategic collaboration aims to advance comprehensive cancer care by focusing on early cancer detection. Starting immediately, patients who meet specific screening criteria at selected HCA Healthcare physician practices will have access to GRAIL’s Galleri® multi-cancer early detection (MCED) test. The Galleri test, is a liquid biopsy test that can identify a shared cancer signal across over 50 different cancer types through a simple blood draw. It is designed to complement existing single cancer screenings.
To provide crucial support to patients and healthcare providers during the diagnostic process following a positive Galleri test result, the Sarah Cannon Cancer Institute will harness its leading nurse navigation program. Enhancements to the patient experience and outcomes will include standardizing patient and provider education, creating evidence-based diagnostic pathways, and ensuring timely evaluations.
HCA Healthcare Physician Services’ Chief Medical Officer, Chris Ott, MD, FACEP, stated, “As a leader in cancer prevention and care, this is an opportunity to be at the forefront of a new age of cancer screening. This partnership allows us to support our patients and clinicians by offering cutting-edge innovation, including GRAIL’s groundbreaking MCED test, as part of our comprehensive cancer care programs.”
GRAIL recently released results from its PATHFINDER study showing the ability to improve cancer detection rates, but also highlighting concerns with false positives and relatively low overall sensitivity for cancer in the trial. Additionally, the European Commission recently ordered Illumina to divest GRAIL due to antitrust concerns.